Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission
VADUZ, Liechtenstein, Feb. 13, 2025 /PRNewswire/ — Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that U.
Outokumpu financial statements release 2024 – Full-year adjusted EBITDA EUR 177 million with historically low stainless steel deliveries
HELSINKI, Feb. 13, 2025 /PRNewswire/ — Highlights in Q4 2024 Stainless steel deliveries were 422,000 tonnes (450,000 tonnes)*. Adjusted EBITDA amounted to EUR -3 million (EUR 72 million). EBITDA was EUR -12 million (EUR 15 million). ROCE amounted to -1.2% (-2.1%). Free cash flow was
" title="Based on Two-time winner of the Japan Character Awards Grand Prix, “Chiikawa” The first smartphone app “Chiikawa Pocket” Launching in 43 countries and regions worldwide in late March 2025
TOKYO, Feb. 13, 2025 /PRNewswire/ — Applibot, Inc. (Headquarters: Shibuya, Tokyo; President: Koki Ukita) is launching a smartphone app “Chiikawa Pocket,” in 43 countries and regions worldwide in late March 2025. Based on the popular manga “Chiikawa” posted on X (formerl
Sinch AB: Year-end report, January-December 2024
STOCKHOLM, Feb. 13, 2025 /PRNewswire/ — Focused on the path ahead October – December 2024 Net sales increased by 3 percent to SEK 7,729m (7,532). Gross profit increased by 2 percent to SEK 2,582m (2,526). EBITDA declined by 63 percent to SEK 307m (818) and was negatively affected by a one-ti
Inceptio Technology Spotlighted in ARK Invest Big Ideas 2025 Report for Autonomous Trucking Leadership
SHANGHAI, Feb. 13, 2025 /PRNewswire/ — Inceptio Technology (“Inceptio” or the “Company”), an industry leading developer of autonomous driving technologies for heavy-duty trucks, today announced it was recognized in ARK Invest’s Big Ideas 2025 report as the undispu
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
The first optogenetic “Chimeric Rhodopsin” gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients. TOKYO, Feb. 13, 2025 /PRNewswire/ — Restore Vision Inc., a clinical-stage biotechn
InventHelp Inventors Develop New Axle Sleeve for Trucks & Trailers (TRO-1247)
PITTSBURGH, Dec. 16, 2024 /PRNewswire/ — “We thought there should be a way to alert a truck driver if axle bearings are overheating,” said one of two inventors, from Leamington, Ontario, Canada, “so we invented the J J HEAT SENSOR. Our design ensures the problem is detected
Media advisory – Governor General to undertake official visit to Alberta
OTTAWA, ON, Oct. 24, 2024 /CNW/ – Their Excellencies the Right Honourable Mary Simon, Governor General of Canada, and Mr. Whit Fraser will undertake an official visit to Alberta from October 25 to 29, 2024. The visit to Alberta will focus on reconciliation, diversity and inclusion, digital res
Colorado Youth Sports Giving Day Raises More Than $3.7M to Boost Access to Youth Sports
DENVER, Oct. 3, 2024 /PRNewswire/ — The Daniels Fund and Project Play Colorado, in collaboration with youth sports nonprofits across the state, proudly announce the success of the inaugural Colorado Youth Sports Giving Day campaign. With more than $3.7 million raised, this initiative will sup
Virtual Internet Announces Virtual Web for the Apple Platform
Virtual Web is first of its kind on the Apple iOS Platform and extends the Virtual Internet Global Service and brand to Apple Virtual Web bridges Apple iOS, Google Android and Microsoft Windows Platforms SINGAPORE and SAN JOSE, Calif., Oct. 3, 2024 /PRNewswire/ — Virtual Internet announced th
